Search Results - "immunogenicity"

Immunogenicity and safety of a trivalent inactivated influenza vaccine produced in Shenzhen, China versus a comparator influenza vaccine: a phase IV randomized study by Yuemei Hu, Kai Chu, Nathalie Lavis, Xiaoling Li, Bill Liang, Shuzhen Liu, Ming Shao, Jean-Denis Shu, Cynthia Tabar, Sandrine Samson

Connect to this object online.

Comparison of immunogenicity between hepatitis B vaccines with different dosages and schedules among healthy young adults in China: A 2-year follow-up study by Zhen-Zi Wang, Yu-Hua Gao, Ping Wang, Lin Wei, Chang-Ping Xie, Zhen-Xing Yang, Jian Lan, Zhong-Liao Fang, Ying Zeng, Ling Yan, Xue-En Liu, Hui Zhuang

Connect to this object online.

An open, non-randomised, phase 1/2 trial on the safety, tolerability, and immunogenicity of single-dose vaccine "Sputnik Light" for prevention of coronavirus infection in healthy adults by Amir I. Tukhvatulin, Inna V. Dolzhikova, Dmitry V. Shcheblyakov, Olga V. Zubkova, Alina S. Dzharullaeva, Anna V. Kovyrshina, Nadezhda L. Lubenets, Daria M. Grousova, Alina S. Erokhova, Andrei G. Botikov, Fatima M. Izhaeva, Olga Popova, Tatiana A. Ozharovskaia, Ilias B. Esmagambetov, Irina A. Favorskaya, Denis I. Zrelkin, Daria V. Voronina, Dmitry N. Shcherbinin, Alexander S. Semikhin, Yana V. Simakova, Elizaveta A. Tokarskaya, Maksim M. Shmarov, Natalia A. Nikitenko, Vladimir A. Gushchin, Elena A. Smolyarchuk, Tatiana G. Zubkova, Konstantin A. Zakharov, Vasiliy B. Vasilyuk, Sergei V. Borisevich, Boris S. Naroditsky, Denis Y. Logunov, Alexander L. Gintsburg

Connect to this object online.

Corrigendum: Clinical Protocol for a Longitudinal Cohort Study Employing Systems Biology to Identify Markers of Vaccine Immunogenicity in Newborn Infants in The Gambia and Papua New Guinea by Olubukola T. Idoko, Olubukola T. Idoko, Olubukola T. Idoko, Olubukola T. Idoko, Kinga K. Smolen, Kinga K. Smolen, Oghenebrume Wariri, Abdulazeez Imam, Casey P. Shannon, Tida Dibassey, Joann Diray-Arce, Joann Diray-Arce, Alansana Darboe, Julia Strandmark, Rym Ben-Othman, Oludare A. Odumade, Oludare A. Odumade, Oludare A. Odumade, Kerry McEnaney, Kerry McEnaney, Nelly Amenyogbe, William S. Pomat, Simon van Haren, Simon van Haren, Guzmán Sanchez-Schmitz, Guzmán Sanchez-Schmitz, Ryan R. Brinkman, Ryan R. Brinkman, Hanno Steen, Hanno Steen, Hanno Steen, Robert E. W. Hancock, Scott J. Tebbutt, Scott J. Tebbutt, Scott J. Tebbutt, Peter C. Richmond, Peter C. Richmond, Anita H. J. van den Biggelaar, Tobias R. Kollmann, Ofer Levy, Ofer Levy, Ofer Levy, Al Ozonoff, Al Ozonoff, Beate Kampmann, Beate Kampmann

Connect to this object online.

Immunogenicity and safety of a multi-dose quadrivalent inactivated influenza vaccine in individuals aged 6 months to 17 years: a randomized phase III trial by Joyce Ojeda, José Luis Arredondo, Perla Salcedo, Mercedes Paredes-Paredes, Martin Dupuy, Celine Petit, Anne Laure Chabanon, Enrique Rivas, Sanjay Gurunathan, Iris De Bruijn, Stephanie Pepin

Connect to this object online.

Immunogenicity and safety of MenACWY-TT, a quadrivalent meningococcal tetanus toxoid conjugate vaccine recently licensed in the United States for individuals ≥2 years of age by Gary S. Marshall, Stephen I. Pelton, Corwin A. Robertson, Philipp Oster

Connect to this object online.

Systemic and Oral Immunogenicity of Porcine Epidemic Diarrhea Virus Antigen Fused to Poly-Fc of Immunoglobulin G and Expressed in ΔXT/FT Nicotiana benthamiana Plants by Nguyen-, Nguyen-, Moon-Sik Yang, Moon-Sik Yang, Yong-Suk Jang, Tae-Ho Kwon, Rajko Reljic, Mi-young Kim, Mi-young Kim

Connect to this object online.

Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection by Yufei Wang, Wanbo Tai, Jie Yang, Guangyu Zhao, Shihui Sun, Chien-Te K. Tseng, Shibo Jiang, Yusen Zhou, Lanying Du, Jimin Gao

Connect to this object online.

Immunogenicity, antibody persistence, and safety of the 60 μg hepatitis B vaccine in hemodialysis patients: a multicenter, randomized, double-blind, parallel-controlled trial by Yongliang Feng, Xiaohong Shi, Jing Shi, Linying Gao, Guangming Liu, Yanpeng Cheng, Minghu Pan, Chunxia Li, Jun Wang, Xuxia Guo, Yawei Zhang, Xiaofeng Liang, Suping Wang

Connect to this object online.

Immunogenicity of a 20-valent pneumococcal conjugate vaccine in adults 18 to 64 years old with medical conditions and other factors that increase risk of pneumococcal disease by Charu Sabharwal, Vani Sundaraiyer, Yahong Peng, Lisa Moyer, Todd J. Belanger, Bradford D. Gessner, Luis Jodar, Kathrin U. Jansen, William C. Gruber, Daniel A. Scott, Wendy Watson

Connect to this object online.

Immunogenicity and safety of a 12-valent pneumococcal conjugate vaccine in infants aged 6-10 weeks: a randomized double-blind active-controlled trial by Jonghoon Shin, Jamaree Teeratakulpisarn, Thanyawee Puthanakit, Tuangtip Theerawit, Ji Hwa Ryu, Jinhwan Shin, Seulgi Lee, Hayoung Lee, Kyungjun An, Hun Kim

Connect to this object online.

Immunogenicity of sequential inactivated and oral poliovirus vaccines (OPV) versus inactivated poliovirus vaccine (IPV) alone in healthy infants: A systematic review and meta-analysis by Guihua Tang, Wen Yin, Youde Cao, Liming Tan, Shuyu Wu, Yudong Cao, Xianyong Fu, Jing Yan, Xingjun Jiang

Connect to this object online.

A randomized phase 1/2 study of the safety and immunogenicity of a multivalent pneumococcal conjugate vaccine in healthy adults 50 through 85 years of age by Brandon Essink, James Peterson, Kari Yacisin, Himal Lal, Sarah Mirza, Xia Xu, Ingrid L. Scully, Daniel A. Scott, William C. Gruber, Kathrin U. Jansen, Wendy Watson

Connect to this object online.

Safety and immunogenicity of a multivalent pneumococcal conjugate vaccine given with 13-valent pneumococcal conjugate vaccine in healthy infants: A phase 2 randomized trial by Michael W. Simon, Regine Bataille, Nicole S. Caldwell, Bradford D. Gessner, Luis Jodar, Erik Lamberth, Yahong Peng, Daniel A. Scott, Lanyu Lei, Peter C. Giardina, William C. Gruber, Kathrin U. Jansen, Allison Thompson, Wendy Watson

Connect to this object online.

CLINICAL STUDIES OF REACTOGENICITY, SAFETY AND IMMUNOGENICITY OF LIVE MONOVALENT INFLUENZA VACCINE (STRAIN А/17/CALIFORNIA/2009/38 - H1N1) IN CHILDREN by D.S. Bushmenkov, A.N. Mironov, A.A. Romanova, A.A. Tsaan, I.V. Feldblyum

Connect to this object online.

Pre-marketing immunogenicity and safety of a lyophilized purified human diploid cell rabies vaccine produced from microcarrier cultures: a randomized clinical trial by Xingyu Zhou, Xiaohong Wu, Yong Cai, Shouchun Cao, Xiaoping Zhu, Qiang Lv, Huaigong Chen, Leitai Shi, Jia Li, Xinjie Wang, Yuhua Li, Rong Zhou

Connect to this object online.

Preventive Efficacy, Safety, Immunogenic Activity, and Evaluation of Post-Vaccination Responses Following Immunization with Combined Trivalent Vaccine Vaktrivir (Measles-Rubella-Parotitis) in Premature Infants by Vadislav V. Semerikov, Nina O. Yаkobyuk, Lyudmila V. Sofronova, Nadezhda V. Yuminova, Natalia N. Vorobjeva, Nikolay A. Kontarov

Connect to this object online.

DENV-3 precursor membrane (prM) glycoprotein enhances E protein immunogenicity and confers protection against DENV-2 infections in a murine model by Roberto S. Dias, Michelle D. Teixeira, Mariana F. Xisto, John W. O. Prates, Jessica D. Da Silva, Iago O. Mello, Cynthia C. Da Silva, Sérgio O. De Paula

Connect to this object online.

High-Level Expression of Immunogenic Recombinant Plasmodium vivax Merozoite Surface Protein (Pvmsp-142 kDa) in pGEX 6P1 Vector by Hadi Mirahmadi, Shirzad Fallahi, Vahid Fallah Omrani, Bahram Kazemi, Ali Haghighi, Seyyed Javad Seyyed Tabaei

Connect to this object online.

Perfluorooctyl bromide nanoemulsions holding MnO2 nanoparticles with dual-modality imaging and glutathione depletion enhanced HIFU-eliciting tumor immunogenic cell death by Xinping Kuai, Yuefei Zhu, Zheng Yuan, Shengyu Wang, Lin Lin, Xiaodan Ye, Yiping Lu, Yu Luo, Zhiqing Pang, Daoying Geng, Bo Yin

Connect to this object online.